Veltuzumab
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name |
Chemical Data
C H N O Molecular Weight | ||
Veltuzumab is a monoclonal antibody designed for the treatment of cancer and autoimmune diseases. It specifically targets the CD20 molecule found on the surface of B cells, which are a type of white blood cell involved in the immune response. By binding to CD20, veltuzumab initiates the destruction of B cells, which is beneficial in conditions where B cells are malignant or are contributing to pathogenic autoimmunity.
Mechanism of Action[edit | edit source]
Veltuzumab functions by binding to the CD20 antigen on B cells. This binding initiates cellular cytotoxicity and leads to the depletion of B cells. The reduction in B cell population helps in reducing the pathological activity in autoimmune diseases and contributes to the destruction of malignant B cells in cancers such as non-Hodgkin lymphoma.
Clinical Uses[edit | edit source]
Veltuzumab has been investigated in several clinical trials for its efficacy and safety in treating conditions like non-Hodgkin lymphoma and chronic lymphocytic leukemia. It has also been studied for potential use in treating autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.
Development and Approval[edit | edit source]
The development of veltuzumab has involved various phases of clinical trials to assess its therapeutic potential and safety profile. As of the last update, veltuzumab has not yet received approval from major regulatory bodies like the U.S. Food and Drug Administration (FDA) for any indication, and it remains under investigation.
Side Effects[edit | edit source]
Like other monoclonal antibodies targeting B cells, veltuzumab can cause side effects, including infusion reactions, infections due to immunosuppression, and potential long-term effects on the immune system. Clinical trials continue to monitor these aspects to better understand the risk profile of veltuzumab.
Future Directions[edit | edit source]
Research continues to explore the full potential of veltuzumab in various therapeutic areas. Future studies are expected to define its role in treatment protocols, possibly in combination with other therapeutic agents.
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
